Maci 3CM x 5CM implant sheets
Ended Awarded Last action
- Contract number
- SPE2DR26FKAP6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $63,176
Award facts
- Contract value 100% obligated
- $63,175.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $63,175.92 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for MACI 3cm x 5cm implant sheets. The award, issued on December 1, 2025, with an ultimate completion date of December 22, 2025, represents a delivery order issued under the agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. DMS Pharmaceutical Group holds a single-award Indefinite Delivery Contract under this broader $30.3 billion acquisition strategy, which was awarded on November 13, 2025, with a $499.99 million ceiling value and extends through December 31, 2036. No set-aside designation was used for this delivery order, demonstrating the contractor's competitive capability in unrestricted federal procurement.
MACI (matrix-applied characterized autologous mesenchymal cells) implants are specialized surgical products used in cartilage repair and regenerative medicine applications for military healthcare facilities. This delivery order reflects DMS Pharmaceutical Group's established role as a critical pharmaceutical and medical consumables supplier within the Department of Defense's global medical supply chain. The company's demonstrated performance across diverse product categories—ranging from oncology treatments and biologics to specialty surgical products and routine pharmaceuticals—positions it to fulfill the specialized medical requirements of military healthcare operations worldwide under the PPV-G GEN V contract vehicle.
Quick answers
Who was awarded contract SPE2DR26FKAP6?
SPE2DR26FKAP6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 1, 2025.
How much is contract SPE2DR26FKAP6 worth?
The government has obligated $63,176 on SPE2DR26FKAP6.
Is contract SPE2DR26FKAP6 an order under another contract?
Yes. SPE2DR26FKAP6 is a delivery order under SPE2DR25D9365, an indefinite delivery contract.
Was contract SPE2DR26FKAP6 competed?
The extent of competition for SPE2DR26FKAP6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award